Dengue Literature Review

Philippines

2 min read

Philippines

Overview

The Philippines is a dengue-endemic archipelago in Southeast Asia, experiencing year-round transmission with marked seasonal peaks during the rainy season (June–November). All four DENV serotypes circulate, making secondary heterotypic infections common. The country is a major contributor to dengue research in the Western Pacific region, with several well-established clinical research sites.

Key Points from Literature

Manila dengue cohort — secondary infection and PAIgG/PAIgM thrombocytopenia (two consecutive studies)

Two consecutive studies from the Nagasaki University / Manila collaboration investigated platelet-associated immunoglobulins in secondary dengue at the same two institutions:

Oishi2003 - PAIgG and Thrombocytopenia in Secondary Dengue (June–November 2001 dengue season):

  • San Lazaro Hospital (Blood Borne Diseases Ward, Manila): primary enrolment site
  • St. Luke’s Medical Center (Research and Biotechnology Division, Quezon City): healthy volunteer controls and laboratory support
  • n=53 confirmed secondary-infection patients (mean age 16.1 ± 7.6 years, 60.4% male); PAIgG inversely correlated with platelet count (r = −0.570, P < 0.0001); anti-dengue IgG confirmed in platelet eluates; anti-platelet autoantibody essentially absent (1/53 patients)

Saito2004 - PAIgG and PAIgM in Secondary Dengue (September 2002–November 2003):

  • Same two institutions; extended study including PAIgM alongside PAIgG; n=78 secondary-infection patients (40 DF, 38 DHF I–II; mean age 18.2 ± 5.9 years) + 43 healthy controls
  • Both PAIgG and PAIgM inversely correlated with platelet count; both fell during convalescence; anti-dengue IgG and IgM activity confirmed in platelet eluates
  • PAIgM >20 ng/10⁷ platelets predicts DHF with 92.1% specificity (48.6% sensitivity) — a potential clinical tool for identifying secondary-infection patients at highest DHF risk

Together, the two studies establish the Philippines as the primary site for the dengue PAIgG/PAIgM thrombocytopenia research programme.

Contradictions & Debates

  • No geographic comparators for these studies in the wiki; the Philippine cohort’s PAIgG/PAIgM mechanism has not been replicated in other Southeast Asian countries at equivalent mechanistic detail.
  • The Saito2004 cohort included only DHF grades I–II (no shock); generalisability to DSS is uncertain.

Sources

Graph View

Backlinks